Clinical Trials Browser

Phase 1/2 × nabiximols × Tumor-Agnostic × Clear all

NCT01812603 2022-12-20

A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma

Phase 1/2 Completed

Neoplasms

NCT01812616 2022-12-20

A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients

Phase 1/2 Completed

Neoplasms